AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AVEO, MHLD, KHC and AMRN

February 27, 2019

CEDARHURST, N.Y., Feb. 27, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)Investors Affected: August 4, 2016 - January 31, 2019

A class action has commenced on behalf of certain shareholders in AVEO Pharmaceuticals, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the TIVO‑3 trial was inadequately designed to address the OS concerns regarding AVEO’s lead candidate drug, tivozanib, from the TIVO-1 trial presented in June 2013; (ii) tivozanib had insufficient survival data to meet FDA approval following its initial 2013 rejection; (iii) this lack of sufficient survival data would put tivozanib at greater risk of delayed FDA approval; and (iv) as a result, AVEO’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/aveo-pharmaceuticals-inc-loss-submission-form/?wire=3

Maiden Holdings, Ltd. (NASDAQGS: MHLD)Investors Affected: March 4, 2014 - November 9, 2018

A class action has commenced on behalf of certain shareholders in Maiden Holdings, Ltd. The complaint alleges that during the Class Period, defendants misrepresented the quality and nature of Maiden’s underwriting and risk management policies and practices and the risks of its reinsurance portfolio. In particular, defendants misleadingly claimed that they were subjecting AmTrust’s insurance portfolio to robust analysis and cross-checks to ensure that the Company had appropriately priced the risk of reinsuring AmTrust’s insurance portfolio. In truth, the Company had failed to employ sufficient underwriting and risk management protocols and had largely abdicated its responsibility to ensure that its AmTrust Reinsurance segment priced policies commensurate with the risk assumed by the Company.

Shareholders may find more information at https://kclasslaw.com/securities/maiden-holdings-ltd-loss-submission-form/?wire=3

The Kraft Heinz Company (NASDAQ: KHC)Investors Affected: May 4, 2017 - February 21, 2019

A class action has commenced on behalf of certain shareholders in The Kraft Heinz Company. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Kraft’s internal controls, specifically with respect to its procurement area, were inadequate; (2) Kraft would be forced to write down a significant amount of goodwill and certain intangible assets in its Kraft natural cheese business, its Oscar Mayer cold cuts business, and its Canada retail business due to supply chain issues; (3) Kraft failed to advise investors of the foregoing issues; and (4) as a result, Kraft’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/the-kraft-heinz-company-loss-submission-form/?wire=3

Amarin Corporation (NASDAQGM: AMRN)Investors Affected: September 24, 2018 - November 9, 2018

A class action has commenced on behalf of certain shareholders in Amarin Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/amarin-corporation-loss-submission-form/?wire=3

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock.

CONTACT:Kuznicki Law PLLCDaniel Kuznicki, Esq.445 Central Avenue, Suite 334Cedarhurst, NY 11516Email: dk@kclasslaw.com Phone: (347) 696-1134Cell: (347) 690-0692Fax: (347) 348-0967

All contents © copyright 2019 The Associated Press. All rights reserved.